Tarceva’s Paucity Of EGFR Status Data Reflects “Emerging Problem” – FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
A possible lack of survival benefit for Tarceva in epidermal growth factor receptor-negative patients led FDA to require postmarketing studies addressing receptor status, despite OSI’s insistence that EGFR status is “not important,” review documents state.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011